Altimmune is trading 5.25% down now at $3.07, primarily amid broader biotech weakness as investors reduce exposure to growth-oriented biotechnology ahead of Federal Reserve Chair Kevin Warsh’s Jackson Hole speech and potential hawkish rate signals.
- XBI is down 2.31%.
- No new company-specific announcement, filing, downgrade, or clinical update was identified for August 28, 2026.
- Altimmune’s latest major disclosures were its August 12 financial update and earlier pemvidutide developments.